Protagonist Therapeutics (NASDAQ:PTGX) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Friday.
Several other analysts have also commented on PTGX. Zacks Investment Research lowered Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 18th. BMO Capital Markets dropped their price objective on Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 19th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $32.67.
Shares of Protagonist Therapeutics (PTGX) traded down $0.05 during mid-day trading on Friday, reaching $18.99. The company had a trading volume of 116,376 shares, compared to its average volume of 85,215. Protagonist Therapeutics has a 52 week low of $8.00 and a 52 week high of $21.68.
In other news, insider David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $16.97, for a total value of $118,790.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Thomas P. O’neil sold 8,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $20.00, for a total value of $160,000.00. Following the completion of the sale, the chief financial officer now directly owns 4,000 shares in the company, valued at $80,000. The disclosure for this sale can be found here. Insiders sold 22,944 shares of company stock worth $438,629 over the last ninety days. Corporate insiders own 15.50% of the company’s stock.
Several large investors have recently modified their holdings of PTGX. Rhumbline Advisers acquired a new stake in shares of Protagonist Therapeutics in the second quarter worth approximately $114,000. Bank of New York Mellon Corp boosted its stake in shares of Protagonist Therapeutics by 5.7% in the second quarter. Bank of New York Mellon Corp now owns 27,626 shares of the company’s stock worth $313,000 after acquiring an additional 1,478 shares during the last quarter. Teachers Advisors LLC boosted its stake in shares of Protagonist Therapeutics by 71.4% in the second quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock worth $183,000 after acquiring an additional 6,757 shares during the last quarter. TIAA CREF Investment Management LLC boosted its stake in shares of Protagonist Therapeutics by 19.5% in the second quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock worth $264,000 after acquiring an additional 3,812 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Protagonist Therapeutics by 24.0% in the second quarter. Northern Trust Corp now owns 98,825 shares of the company’s stock worth $1,118,000 after acquiring an additional 19,159 shares during the last quarter. 39.68% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/21/protagonist-therapeutics-ptgx-lowered-to-sell-at-bidaskclub.html.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.